ArticleClinical and translational science2025
A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P-gp and BCRP Substrates in Healthy Subjects.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05368805 (A Phase 1, Open-label, 2-part, 2-period Fixed-sequence Study to Evaluate the Effect of Fruquintinib on the Pharmacokinetics of Dabigatran Etexilate), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Open-label, 2-part, 2-period Fixed-sequence Study to Evaluate the Effect of Fruquintinib on the Pharmacokinetics of Dabigatran Etexilate (A P-GP Substrate) and Rosuvastatin (A BCRP Substrate) in Healthy Subjects
Who cites it
1 citing paper in PubMed.
- Fruquintinib: Mechanism of Action, Clinical, and Translational Science.Clinical and translational science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fruquintinib, a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (-1, -2, and -3), is approved for previously treated metastatic colorectal cancer. This phase 1, two-part, two-period, fixed-sequence study (NCT05368805) evaluated the potential inhibitory effect of fruquintinib (5 mg) on the pharmacokinetics (PK) of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) substrates. In Part A, 20 healthy subjects received a single oral dose of dabigatran etexilate (P-gp substrate) 150 mg on Day 1 and Day 5, with fruquintinib co-administered on Day 5. In Part B, 12 healthy subjects received a single oral dose of rosuvastatin (BCRP substrate) 10 mg on Day 1 and Day 5, with fruquintinib co-administered on Day 5. Plasma samples were collected to evaluate the PK of dabigatran and rosuvastatin over 96 h, and to measure fruquintinib and its major metabolite M11 concentrations over 192 h. Co-administration of dabigatran etexilate with fruquintinib resulted in a ~10% decrease in the systemic exposure of dabigatran; geometric mean ratios (GMRs) and 90% CIs were 0.90 (0.66-1.23) for C
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.